Hormone FDA Approved

Lanreotide

A long-acting somatostatin analog marketed as Somatuline Depot and used in neuroendocrine and acromegaly-related care.

Somatostatin AnalogFDA ApprovedAcromegalyNeuroendocrine

Also referenced as: Somatuline Depot, Lanreotide Acetate

Public product evidence No certificate records are bound to a tracked Lanreotide product page A record counts here only when a vendor publishes a certificate against one of its own tracked Lanreotide product pages. Other certificates naming this compound may still exist — search the wider certificate database.
Status
FDA Approved

This compound maps to at least one regulated medical product or label context in the United States.

Research area
Hormone signaling research

This profile is grouped by its dominant research area, not by vendor shelf placement.

Body systems
Hormones

Where the compound acts, as a browse axis. It is an editorial grouping for discovery, not a claim about labeled indications.

Aliases
2

Somatuline Depot, Lanreotide Acetate

Signal depth
High

FDA label signal · 125 trials · 1242 PubMed results

Established
Research evidence

Lanreotide is an FDA-approved medicine with substantial published trial evidence. Note that research-market products sold under this name are not the approved medicine and are not held to the same manufacturing or labeling standards.

Lanreotide has 58 name-matched clinical trials (1 international) (highest phase: Phase 4) and 1242 PubMed-indexed publications and holds an FDA drug label. 18 trials have posted results.

🌍 1 international trial FAERS (approved drug): 4,759
Human data
Approved drug
Trial quality
Large RCT
Outcomes
Clinical outcomes
Replication
Meta-analysis
Literature
Top-tier journals
PHASE4 Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects PHASE4 · Randomized A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide PHASE4 Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET ISRCTN Assessment of the efficacy of Lanreotide Autogel® in the reversal of sleep apnoea, left ventricular hypertrophy and hypertension when used as primary medical therapy in acromegaly New England Journal of Medicine · 1,937 citations Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors Journal of Clinical Oncology · 499 citations Prospective, Randomized, Multicenter Trial on the Antiproliferative Effect of Lanreotide, Interferon Alfa, and Their Combination for Therapy of Metastatic Neuroendocrine Gastroenteropancreatic Tumors—The International Lanreotide and Interferon Alfa Study Group
Evidence history

Re-checked nightly against the registries — tracked since 2026-07-09. No band changes yet.

Grades evidence strength, not efficacy or safety. Research-use context; not medical advice. Graded 2026-11-02 from PubMed, ClinicalTrials.gov, ISRCTN, openFDA, Health Canada, and OpenAlex — computed deterministically and refreshed nightly, with a retraction check. How we grade →

What lanreotide is

Lanreotide is a long-acting somatostatin analog best known in the United States as Somatuline Depot.

Why it matters

It rounds out the approved somatostatin-analog side of the peptide library and gives users a more complete picture of serious peptide therapeutics in endocrine medicine.

Regulatory context

Lanreotide is FDA approved in the United States.

Practical reading note

When a peptide has deep real-world use in medicine, it often deserves a page even if it is not a gray-market conversation magnet.